The first line of treatment is usually weight loss through a combination of a healthy diet and exercise. Losing weight addresses the conditions that contribute to nonalcoholic fatty liver disease. Ideally, a loss of 10 percent of body weight is desirable, but improvement in risk factors can become apparent if you lose even three to five percent of your starting weight. Weight-loss surgery is also an option for those who need to lose a great deal of weight.
Your doctor may recommend that you receive vaccinations against hepatitis A and hepatitis B to help protect you from viruses that may cause further liver damage.
For those who have cirrhosis due to nonalcoholic steatohepatitis, liver transplantation may be an option. Outcomes of liver transplant in this population group are generally very good.
Potential future treatments
No FDA-approved drug treatment exists for nonalcoholic fatty liver disease, but a few drugs are being studied with promising results.
No alternative medicine treatments are proved to cure nonalcoholic fatty liver disease. But researchers are studying whether some natural compounds could be helpful, such as:
Vitamin E. In theory, vitamin E and other vitamins called antioxidants could help protect the liver by reducing or neutralizing the damage caused by inflammation. But more research is needed.
Some evidence suggests vitamin E supplements may be helpful for people with liver damage caused by nonalcoholic fatty liver disease. But vitamin E has been linked with increased risk of death and, in men, an increased risk of prostate cancer.
Coffee. In studies of people with nonalcoholic fatty liver disease, those who reported drinking coffee had less liver damage than those who drank little or no coffee. It's not clear how coffee may influence liver damage or how much coffee you'd need to drink in order to benefit.
If you already drink coffee, these results may make you feel better about your morning cup of coffee. But if you don't already drink coffee, this probably isn't a good reason to start. Discuss the potential benefits of coffee with your doctor.
Aug. 23, 2016
- Chalasani N, et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases and American College of Gastroenterology. Gastroenterology. 2012;142:1592.
- Feldman M, et al. Nonalcoholic fatty liver disease. In: Sleisenger & Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. 10th ed. Philadelphia, Pa.: Saunders Elsevier; 2016. http://www.clinicalkey.com. Accessed May 10, 2016.
- Rinella M. Nonalcoholic fatty liver disease: A systematic review. Journal of the American Medical Association. 2015;313:2263. http://jama.jamanetwork.com/ Accessed May 10, 2016.
- Spengler E, et al. Recommendations for diagnosis, referral for liver biopsy, and treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. http://www.mayoclinicproceedings.org/article/S0025-6196(15)00510-8/abstract. Mayo Clinic Proceedings. 2015;90:1233. Accessed May 10, 2015.
- Barbara Woodward Lips Patient Education Center. Nonalcoholic fatty liver disease. Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2009.
- Venkatesh SK, et al. Magnetic resonance elastography of liver: Technique, analysis and clinical applications. Journal of Magnetic Resonance Imaging. 2013;37:544.
- Kim D, et al. Advanced fibrosis in nonalcoholic fatty liver disease: Noninvasive assessment with MR elastography. Radiology. 2013;268:411.
- Sheth SG, et al. Nonalcoholic fatty liver disease: Natural history and management. http://www.uptodate.com/home. Accessed May 10, 2016.
- Boyer TD, et al. Nonalcoholic fatty liver disease. In: Zakim & Boyer's Hepatology: A Textbook of Liver Disease. 6th ed. Philadelphia, Pa: Saunders Elsevier, 2012. http://www.clinicalkey.com. Accessed May 10, 2015.
- Molloy JW, et al. Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis and degree of hepatic fibrosis. Hepatology. 2012;55:429.
- Malhi H, et al. Nonalcoholic fatty liver: Optimizing pretransplant selection and posttransplant care to maximize survival. Current Opinion in Organ Transplantation. 2016, 21:99.
- Heimbach J, et al. Combined liver transplantation and gastric sleeve resection for patients with medically complicated obesity and end-stage liver disease. American Journal of Transplantation. 2013; 13:363.
- Watt KD (expert opinion). Mayo Clinic, Rochester, Minn. Personal communication. July 7, 2016.
- Ludwig J, et al. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clinic Proceedings. 1980;55:434.
- Uppal V, et al. Pediatric non-alcoholic fatty liver disease. Current Gastroenterology Reports. 2016;18:24.
Nonalcoholic fatty liver disease